Effect of Lipopolysaccharide on Skeletal Muscle Functions (LPS)
Primary Purpose
Sepsis
Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Lipopolysaccharide infusion
saline
Sponsored by
About this trial
This is an interventional basic science trial for Sepsis focused on measuring Sepsis, Inflammation, Lipopolysaccharide, Muscle protein turnover, Insulin resistance
Eligibility Criteria
Inclusion Criteria:
Male 18-30yrs
Exclusion Criteria:
Clotting disorders Metabolic disease e.g. diabetes, thyroid dysfunction Inflammatory conditions e.g. Crohn's Disease Tobacco smoker Cardiac or Renal pathology Respiratory problems including Asthma Active infectious conditions
Sites / Locations
- Queens Medical Centre
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Lipopolysaccharide infusion
saline
Arm Description
Lipopolysaccharide infusion; dosage 4ng/kg body weight
0.9% saline infusion
Outcomes
Primary Outcome Measures
Skeletal Muscle Protein Turnover (muscle tracer incorporation)
incorporation of 1,2 13C-leucine into muscle tissue
Secondary Outcome Measures
Whole body glucose disposal
Glucose uptake calculated from glucose infused to maintain euglycemia during a constant insulin infusion.
Expression of genes that regulate muscle protein balance and insulin signalling
Changes in mRNA levels of several transcripts associated with metabolism or muscle growth in skeletal muscle
Full Information
NCT ID
NCT01423968
First Posted
August 11, 2011
Last Updated
March 23, 2018
Sponsor
University of Nottingham
1. Study Identification
Unique Protocol Identification Number
NCT01423968
Brief Title
Effect of Lipopolysaccharide on Skeletal Muscle Functions
Acronym
LPS
Official Title
Impact & Time-Course of Effect of Intravenous Lipopolysaccharide Infusion on Skeletal Muscle Protein Turnover and Insulin Sensitivity in Healthy Human Volunteers
Study Type
Interventional
2. Study Status
Record Verification Date
March 2018
Overall Recruitment Status
Completed
Study Start Date
July 2011 (Actual)
Primary Completion Date
December 2012 (Actual)
Study Completion Date
December 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Nottingham
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The investigators aim to examine how the skeletal muscles of the human volunteers respond to experimental septic conditions to aid understanding of muscle wasting and its biology..
Six healthy men aged 18-30 will be randomly assigned to two metabolic study visits. On the first visit, while resting on a bed, they will have four cannulae inserted including one in the upper thigh, for blood sampling and the infusion of insulin, glucose and normal and tracer amino acids (which allow us to measure muscle protein metabolism). Subjects will receive either injection of purified bacterial product called lipopolysaccharide (LPS) to induce flu-like symptoms or normal saline according to randomization followed by a metabolic test to stimulate muscle synthesis and glucose transport. Three small samples of muscle will be obtained under local anaesthetic from the thigh to measure molecular events in muscle. By performing these measurements, the investigators will determine the consequences of LPS on muscle production and carbohydrate metabolism.
Detailed Description
During sepsis, the ability of the body to prevent muscle wasting is impaired resulting in loss of skeletal muscle. In addition, skeletal muscle handling of carbohydrate becomes less efficient. These changes could result in delayed recovery, prolonged rehabilitation and in severe cases mortality of patients. It is still unclear how these changes occur in the human skeletal muscles but animal experiments suggest that protein molecules that are released during sepsis are responsible for these changes. Due to the biological differences between animals and humans in metabolic rate and stability, disease susceptibility and response to infection, simple translation of knowledge from animals to patients could be highly misleading. Therefore, we aim to examine how the skeletal muscles of the human volunteers respond to experimental septic conditions.
Following medical screening, six healthy men aged 18-30 will have two metabolic study visits in a random manner. On the first visit, while resting on a bed, they will have four cannulae inserted including one in the upper thigh, for blood sampling and the infusion of insulin, glucose and normal and tracer amino acids (which allow us to measure muscle protein metabolism). Subjects will receive either injection of purified bacterial product called lipopolysaccharide (LPS) to induce flu-like symptoms or normal saline according to randomization followed by a metabolic test to stimulate muscle synthesis and glucose transport. Three small samples of muscle will be obtained under local anaesthetic from the thigh to measure molecular events in muscle. By performing these measurements, we will determine the consequences of LPS on muscle production and carbohydrate metabolism.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sepsis
Keywords
Sepsis, Inflammation, Lipopolysaccharide, Muscle protein turnover, Insulin resistance
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
6 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Lipopolysaccharide infusion
Arm Type
Experimental
Arm Description
Lipopolysaccharide infusion; dosage 4ng/kg body weight
Arm Title
saline
Arm Type
Placebo Comparator
Arm Description
0.9% saline infusion
Intervention Type
Biological
Intervention Name(s)
Lipopolysaccharide infusion
Other Intervention Name(s)
Endotoxin
Intervention Description
Lipopolysaccharide 4 nanogram/kg body weight
Intervention Type
Other
Intervention Name(s)
saline
Other Intervention Name(s)
0.9% saline infusion
Primary Outcome Measure Information:
Title
Skeletal Muscle Protein Turnover (muscle tracer incorporation)
Description
incorporation of 1,2 13C-leucine into muscle tissue
Time Frame
4 hr following LPS infusion
Secondary Outcome Measure Information:
Title
Whole body glucose disposal
Description
Glucose uptake calculated from glucose infused to maintain euglycemia during a constant insulin infusion.
Time Frame
4 h Glucose insulin clamp
Title
Expression of genes that regulate muscle protein balance and insulin signalling
Description
Changes in mRNA levels of several transcripts associated with metabolism or muscle growth in skeletal muscle
Time Frame
4 h following LPS infusion
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
30 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Male 18-30yrs
Exclusion Criteria:
Clotting disorders Metabolic disease e.g. diabetes, thyroid dysfunction Inflammatory conditions e.g. Crohn's Disease Tobacco smoker Cardiac or Renal pathology Respiratory problems including Asthma Active infectious conditions
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Paul L Greenhaff, PhD
Organizational Affiliation
Professor of Muscle Metabolism, University of Nottingham
Official's Role
Principal Investigator
Facility Information:
Facility Name
Queens Medical Centre
City
Nottingham
State/Province
Nottinghamshire
ZIP/Postal Code
NG7 2UH
Country
United Kingdom
12. IPD Sharing Statement
Learn more about this trial
Effect of Lipopolysaccharide on Skeletal Muscle Functions
We'll reach out to this number within 24 hrs